Have your own idea? Try our Stock Screener
U.K. (FTSE) Life Sciences Industry Analysis
UpdatedJun 21, 2026
DataAggregated Company Financials
Companies7
- 7D1.3%
- 3M1.8%
- 1Y-2.2%
- YTD-6.6%
Over the last 7 days, the Life Sciences industry has risen 1.3%, driven by gains from Oxford Nanopore Technologies of 1.5%. In the same time, hVIVO was down 7.1%. Overall in the last year, the industry is flat. Earnings are forecast to grow by 57% annually.
Industry Valuation and Performance
Has the U.K. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 21 Jun 2026 | UK£1.4b | UK£323.0m | -UK£166,018,254.00 | 1291.9x | -8.2x | 4.2x |
| Tue, 19 May 2026 | UK£1.4b | UK£318.2m | -UK£167,469,254.00 | n/a | -8.4x | 4.4x |
| Thu, 16 Apr 2026 | UK£1.4b | UK£323.0m | -UK£156,192,254.00 | 10.9x | -8.7x | 4.2x |
| Sat, 14 Mar 2026 | UK£1.4b | UK£324.0m | -UK£161,423,254.00 | 10.3x | -8.4x | 4.2x |
| Mon, 09 Feb 2026 | UK£1.6b | UK£304.6m | -UK£159,441,254.00 | 7.9x | -10x | 5.3x |
| Wed, 07 Jan 2026 | UK£1.5b | UK£304.6m | -UK£159,441,254.00 | 7.9x | -9.7x | 5.1x |
| Fri, 05 Dec 2025 | UK£1.5b | UK£303.9m | -UK£162,910,254.00 | 6.7x | -8.9x | 4.8x |
| Sun, 02 Nov 2025 | UK£1.6b | UK£304.3m | -UK£163,156,254.00 | 8.5x | -9.5x | 5.1x |
| Tue, 30 Sep 2025 | UK£1.7b | UK£304.0m | -UK£163,375,352.00 | 10.3x | -10.4x | 5.6x |
| Thu, 28 Aug 2025 | UK£2.1b | UK£291.9m | -UK£160,968,352.00 | 6.4x | -13.1x | 7.2x |
| Sat, 26 Jul 2025 | UK£2.2b | UK£291.9m | -UK£160,968,352.00 | 6.4x | -13.9x | 7.7x |
| Mon, 23 Jun 2025 | UK£1.5b | UK£319.6m | -UK£191,020,739.20 | 6.5x | -8x | 4.8x |
| Wed, 21 May 2025 | UK£1.6b | UK£313.7m | -UK£192,298,974.60 | 11.2x | -8.5x | 5.2x |
| Fri, 18 Apr 2025 | UK£1.6b | UK£315.0m | -UK£185,692,789.90 | 6.3x | -8.5x | 5x |
| Sun, 16 Mar 2025 | UK£1.5b | UK£315.6m | -UK£186,194,740.85 | 6.3x | -7.9x | 4.7x |
| Tue, 11 Feb 2025 | UK£1.9b | UK£307.1m | -UK£195,706,532.40 | 7.3x | -9.8x | 6.2x |
| Thu, 09 Jan 2025 | UK£1.9b | UK£307.2m | -UK£195,743,697.84 | 7.2x | -9.7x | 6.2x |
| Sat, 07 Dec 2024 | UK£2.0b | UK£306.1m | -UK£194,891,751.60 | 8.2x | -10.3x | 6.5x |
| Mon, 04 Nov 2024 | UK£1.9b | UK£304.8m | -UK£192,652,400.50 | 11x | -9.9x | 6.3x |
| Wed, 02 Oct 2024 | UK£2.1b | UK£303.9m | -UK£191,909,787.70 | 10.9x | -11.1x | 7x |
| Fri, 30 Aug 2024 | UK£1.8b | UK£295.7m | -UK£188,308,404.90 | 12.5x | -9.6x | 6.1x |
| Sun, 28 Jul 2024 | UK£1.9b | UK£295.4m | -UK£189,801,674.25 | 12.6x | -9.8x | 6.3x |
| Tue, 25 Jun 2024 | UK£1.4b | UK£295.9m | -UK£190,232,433.51 | 11.4x | -7.5x | 4.8x |
| Thu, 23 May 2024 | UK£1.6b | UK£295.7m | -UK£189,870,717.45 | 11x | -8.6x | 5.5x |
| Sat, 20 Apr 2024 | UK£1.5b | UK£317.8m | -UK£178,601,486.69 | 11.5x | -8.2x | 4.6x |
| Mon, 18 Mar 2024 | UK£1.9b | UK£295.6m | -UK£212,950,708.15 | 7176.9x | -8.8x | 6.3x |
| Wed, 14 Feb 2024 | UK£2.1b | UK£286.0m | -UK£189,400,816.69 | 7213.1x | -11.1x | 7.4x |
| Fri, 12 Jan 2024 | UK£2.9b | UK£449.9m | -UK£173,896,551.00 | 68.4x | -16.8x | 6.5x |
| Sun, 10 Dec 2023 | UK£3.0b | UK£453.0m | -UK£170,803,824.00 | 47.2x | -17.3x | 6.5x |
| Tue, 07 Nov 2023 | UK£3.2b | UK£458.1m | -UK£165,145,664.00 | 47.2x | -19.3x | 6.9x |
| Thu, 05 Oct 2023 | UK£2.9b | UK£448.9m | -UK£169,314,935.00 | 60x | -17.4x | 6.6x |
| Sat, 02 Sep 2023 | UK£3.1b | UK£476.5m | -UK£126,777,552.00 | 70.6x | -24.5x | 6.5x |
| Mon, 31 Jul 2023 | UK£3.4b | UK£476.2m | -UK£124,491,061.00 | 69.6x | -27.3x | 7.1x |
| Wed, 28 Jun 2023 | UK£2.9b | UK£476.6m | -UK£124,763,312.00 | 66.1x | -23.4x | 6.1x |
Price to Earnings Ratio
-23.4x
Current Industry PE
- Investors are pessimistic on the British Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.8x is higher than the industry's current PS ratio of 4.2x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Revenues have also declined 12% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | -1.30% | |
| Healthcare | -1.79% | |
| Life Sciences | 1.27% | |
| Clinical Research and Equipment | 1.27% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies | UK£1.17 | 1.5% +UK£16.5m | -2.8% | PS5.1x | |
| DXRX Diaceutics | UK£1.48 | 3.9% +UK£4.7m | 26.5% | PE1291.9x | |
| GDR genedrive | UK£0.013 | 8.3% +UK£1.6m | -13.3% | PS17.8x | |
| FAB Fusion Antibodies | UK£0.13 | 4.2% +UK£625.1k | 93.8% | PS9.8x |